148 related articles for article (PubMed ID: 2138906)
1. Monoclonal antibodies that discriminate between human ovarian carcinomas and benign ovarian tumours.
Boerman OC; Makkink WK; Thomas CM; Hanselaar AG; Yedema CA; Kenemans P; Poels LG
Eur J Cancer; 1990 Feb; 26(2):117-27. PubMed ID: 2138906
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody against human ovarian tumor-associated antigens.
Poels LG; Peters D; van Megen Y; Vooijs GP; Verheyen RN; Willemen A; van Niekerk CC; Jap PH; Mungyer G; Kenemans P
J Natl Cancer Inst; 1986 May; 76(5):781-91. PubMed ID: 3517452
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies against ovarian carcinoma-associated antigens, raised by immunization with cyst fluids.
Boerman O; Makkink K; Massuger L; Thomas C; Kenemans P; Hanselaar T; Poels L
Anticancer Res; 1989; 9(3):551-8. PubMed ID: 2764501
[TBL] [Abstract][Full Text] [Related]
4. Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens.
Boerman OC; van Niekerk CC; Makkink K; Hanselaar TG; Kenemans P; Poels LG
Int J Gynecol Pathol; 1991; 10(1):15-25. PubMed ID: 2007534
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemical detection of ovarian carcinoma cells in serous effusions.
Cuijpers VM; Boerman OC; Salet van de Pol MR; Vooijs GP; Poels LG; Ramaekers FC
Acta Cytol; 1993; 37(3):272-9. PubMed ID: 8498129
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies.
Boerman O; Massuger L; Makkink K; Thomas C; Kenemans P; Poels L
Anticancer Res; 1990; 10(5A):1289-95. PubMed ID: 2241105
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of epithelial ovarian neoplasm immunologic reactivity using monoclonal antibodies].
Bar J; Sobańska E
Ginekol Pol; 1994 Sep; 65(9):502-7. PubMed ID: 7721163
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
Molthoff CF; Pinedo HM; Schlüper HM; Nijman HW; Boven E
Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596
[TBL] [Abstract][Full Text] [Related]
9. Relation between ovarian carcinoma-associated antigens in tumor tissue and detached cyst fluid cells of patients with ovarian neoplasms.
Bar JK; Harłozińska A; Sobańska E; Cislo M
Tumori; 1994 Feb; 80(1):50-5. PubMed ID: 8191599
[TBL] [Abstract][Full Text] [Related]
10. Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue.
Buist MR; Molthoff CF; Kenemans P; Meijer CJ
J Clin Pathol; 1995 Jul; 48(7):631-6. PubMed ID: 7560169
[TBL] [Abstract][Full Text] [Related]
11. Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas.
van Niekerk CC; Boerman OC; Ramaekers FC; Poels LG
Am J Pathol; 1991 Feb; 138(2):455-63. PubMed ID: 1992770
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
[TBL] [Abstract][Full Text] [Related]
13. The sebaceous gland antigen defined by the OM-1 monoclonal antibody is expressed at high density on the surface of ovarian carcinoma cells.
de Kretser TA; Thorne HJ; Jacobs DJ; Jose DG
Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1019-35. PubMed ID: 2998800
[TBL] [Abstract][Full Text] [Related]
14. Marker profile of mesothelial cells versus ovarian carcinoma cells.
van Niekerk CC; Jap PH; Thomas CM; Smeets DF; Ramaekers FC; Poels LG
Int J Cancer; 1989 Jun; 43(6):1065-71. PubMed ID: 2659540
[TBL] [Abstract][Full Text] [Related]
15. Mouse monoclonal antibodies to human epithelial differentiation antigens expressed on the surface of ovarian carcinoma ascites cells.
Mattes MJ; Look K; Furukawa K; Pierce VK; Old LJ; Lewis JL; Lloyd KO
Cancer Res; 1987 Dec; 47(24 Pt 1):6741-50. PubMed ID: 3677104
[TBL] [Abstract][Full Text] [Related]
16. Humoral anti-OV-TL 3 response after the intravenous administration of radiolabelled Fab' or F(ab')2 fragments in ovarian cancer patients.
Tibben JG; Thomas CM; Massuger LF; Segers MF; Schijf CP; Corstens FH; Boerman OC
Nucl Med Commun; 1995 Oct; 16(10):853-9. PubMed ID: 8570116
[TBL] [Abstract][Full Text] [Related]
17. [Distribution and diagnostic role of COTA in mucinous ovarian tumors].
Shi ZL
Zhonghua Zhong Liu Za Zhi; 1989 May; 11(3):191-2. PubMed ID: 2612330
[TBL] [Abstract][Full Text] [Related]
18. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice.
Nässander UK; Steerenberg PA; Poppe H; Storm G; Poels LG; De Jong WH; Crommelin DJ
Cancer Res; 1992 Feb; 52(3):646-53. PubMed ID: 1732053
[TBL] [Abstract][Full Text] [Related]
19. Identification of two different surface epitopes of human ovarian epithelial carcinomas by monoclonal antibodies.
Tsuji Y; Suzuki T; Nishiura H; Takemura T; Isojima S
Cancer Res; 1985 May; 45(5):2358-62. PubMed ID: 2580620
[TBL] [Abstract][Full Text] [Related]
20. Immunocytochemical determination of EGFR, OV 632 and OC 125 in primary ovarian cancer patients.
Athanassiadou P; Athanassiades P; Kyrkou K; Lazaris D; Kyragiannis G; Petrakakou E; Michalas S
Oncology; 1995; 52(2):145-9. PubMed ID: 7854775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
